Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs
Introduction
The continued spread of the human immunodeficiency virus type 1 (HIV-1) worldwide highlights the need for an effective vaccine. Based on studies of HIV-1 infection in humans, and SIV infection of macaques, it is believed that CD8 T-cells play an important role in control of viral replication [1]. It is hoped that vaccine elicited T-cell responses will be able to limit viral replication and prevent HIV-1 associated disease progression in those individuals who become infected. However, antibodies may be required to prevent the acquisition of HIV-1 infection. Neutralizing antibodies can block viral entry into human T-cells in vitro and can protect non-human primates from a chimeric simian-human immunodeficiency virus (SHIV) infection [2], [3]. Thus, a major goal is to develop an HIV-1 vaccine strategy that will generate both cellular immunity and high titers of virus neutralizing antibodies. Serial immunization with HIV-1 envelope (Env) protein immunogens can result in high antibody levels, but little or no CD8 T-cell responses [4], [5], [6], [7], [8], [9]. One approach to generating both cellular immunity and neutralizing antibodies is to initiate immunization with a gene based vector that is known to elicit CD4 and CD8 responses, and boost with a protein immunogen.
Current gene-based immunogens, such as plasmid DNA and rAd5, have been widely studied in animal models [10], [11], [12], [13], [14], [15], and have entered phase I and II human testing [16], [17], [18], [19]. In addition, numerous groups have utilized vector prime, protein boost regimens to improve the potency or durability of the immune response to HIV or SIV antigens [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30]. In this study, we evaluated the ability of our existing clinical vaccine products, multi-gene plasmid DNA and rAd5, to prime for a booster immunization with a soluble oligomeric Env protein. The plasmid DNA and rAd5 vectors used here were the same as those currently being studied in human trials [18], [19]. The DNA product consists of six individual plasmids. Three encode gp145 Env proteins (clade A–C); the remaining three encode Gag, Pol and Nef. The rAd5 product contains four separate rAd5 vectors. Three encode gp140 versions of the same Env proteins as above; a fourth encodes a Gag-Pol fusion protein. Data from non-human primate studies show that a series of three DNA immunizations, or a single rAd5 immunization, generates robust antigen specific CD4 and CD8 responses and moderate antibody levels [31], [32]. Recent phase I studies in humans have confirmed these results [18], [19]. Additionally, the combination of DNA prime, rAd5 boost has been extensively studied in small animals and non-human primates, and results in robust cellular immunity and high antibody levels [13], [32], [33], [34], [35], [36], [37]. However, we have not systematically studied the ability of these DNA or rAd5 vaccine candidates to prime for a protein boost. Thus, these studies focus on the anti-Env response elicited by DNA or rAd5, and boosted with a soluble Env protein.
A soluble oligomeric gp140 Env protein based on the SF162 strain, and containing a deletion of the second variable region (V2), has been studied in animal models and is currently being tested in phase I human trials. Immunization with the dV2gp140 protein generates high titer antibody levels including homologous neutralizing antibodies [6], [38], [39], [40], [41]. In addition, dV2gp140 elicits high antibody titers in monkeys primed with a DNA plasmids encoding the homologous env gene [42], [43]. To further asses the potential for protein boosting of both DNA and rAd5, we formulated the dV2gp140 Env protein with the MF59 adjuvant alone, or with one of two different classes of a synthetic oligodeoxynucleotide (ODN) containing unmethylated deoxycytosine–doexyguanosine (CpG) motifs. GpG ODN are Toll-like receptor 9 (TLR9) ligands that stimulate antigen presenting dendritic cells (DC) [44]. Class A ODN stimulate high levels of INFα from plasmactyoid DC; B-class ODN induce strong B-cell and NK cell activation and the more recently discover C-class ODN appear have properties of both the A- and B-class ODN [45], [46]. Since several ODN adjuvants are in phase I human testing, we evaluated if B and C-class ODN, when formulated with protein in the boost phase of immunization, could augment the antibody response elicited by MF59 alone.
The guinea pig (GP) studies described here were designed to evaluate anti-Env antibody responses elicited by combinations of existing vaccine immunogens that have advanced into human clinical trails. Current HIV-1 DNA and rAd5 vectors are known to elicit robust T-cell responses in humans, but rather modest antibody levels. The soluble dV2gp140 protein elicits high antibody levels, but not CD8 T-cell responses. Thus, in human trials, it might be possible to establish a CD4 and CD8 T-cell response with the appropriate vaccine vectors, and further boost the antibody response with an Env protein. In these GP studies, we observed that a series of three DNA immunizations, or a single rAd5 immunization, produced moderate levels of anti-Env antibody, and effectively primed for boosting with soluble protein. A single protein boost immunization resulted in high antibody levels and the induction of virus neutralizing antibodies. The addition of a B- or C-class ODN to the protein formulation in the boost phase of immunization did not augment the antibody response generated by MF59 alone. While current Env based immunogens do not readily generate broadly reactive neutralizing antibodies, theses data suggest that DNA plus protein, or rAd5 plus protein, are valuable vaccine platforms that can be used to study the generation of HIV-1 anti-Env antibody responses. In addition, it may be possible to establish a T-cell response with appropriate vectored vaccines and further improve the neutralizing antibody titer with protein boosting.
Section snippets
Vaccine constructs
The plasmid DNA vaccine consisted of six individual plasmids each encoding a single HIV-1 gene product. HIV-1 clade B Gag, Pol, and Nef, and a clade A, B and C gp145 env, were each cloned into the expression vector CMV/R containing the human cytomegalovirus immediate early enhancer, promoter and intron region from HTLV-1 [47]. The gene inserts were synthetic codon optimized sequences and have been described previously [48]. The gag gene was derived from the clade B strain HXB2 (GenBank
Immunization protocol
This study was designed to test the effect of protein boosting after priming immunizations with either DNA or rAd5. In all cases, protein was formulated with the MF59 adjuvant. Since an additional objective was to evaluate if CpG ODNs could augment the antibody response produced by the MF59 formulation, we compared the MF59 adjuvant alone, to MF59 plus one of two ODNs (Fig. 1). Note that we were not using the ODN during the primary DNA or rAd5 immunizations, but rather only during the protein
Discussion
It this study, we focused on several HIV-1 candidate vaccines that are being tested in ongoing phase I/II clinical trails; these included a multigene plasmid DNA, a multigene rAd5 vaccine, and a soluble clade B trimeric dV2gp140. While protein immunization can induce high antibody levels, it does not elicit the CD8 T-cell responses that are thought to be important for controlling HIV-1 infection. Since DNA and rAd5 vectors elicit robust cellular immune responses, including CD4 T-cell response
References (59)
- et al.
Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers
Vaccine
(2006) - et al.
Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit
Vaccine
(1997) - et al.
Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine
Virology
(2006) - et al.
Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E
Virology
(2006) - et al.
Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model
Vaccine
(2006) - et al.
Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection
Virology
(2006) - et al.
Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV
Virology
(2004) - et al.
C-Class CpG ODN: sequence requirements and characterization of immunostimulatory activities on mRNA level
Immunobiology
(2004) - et al.
Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate
Vaccine
(2005) - et al.
Evaluation of adjuvants for protein vaccines against tuberculosis in guinea pigs
Vaccine
(2003)
Correlates of immune protection in HIV-1 infection: what we know, what we don’t know, what we should know
Nat Med
HIV vaccine design and the neutralizing antibody problem
Nat Immunol
Defining the protective antibody response for HIV-1
Curr Mol Med
Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous simian/human immunodeficiency virus infection in pigtailed Macaques
J Virol
Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group
J Infect Dis
The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region
J Virol
Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques
J Virol
Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160
J Virol
HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8 + T cell responses in nonhuman primates
Proc Natl Acad Sci USA
Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
Science
Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity
Nature
Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene
J Virol
Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys
J Virol
Rational design of gene-based vaccines
J Pathol
Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge
J Virol
T-cell responses induced in normal volunteers immunized with a DNA-based vaccine containing HIV-1 env and rev
AIDS
Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination
Proc Natl Acad Sci USA
Cited by (72)
Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen ama1: Report on a phase 1a clinical trial
2014, Molecular TherapyCitation Excerpt :Priming with viral vectors also led to enhanced IgG antibody avidity and Th1-type IgG isotype skew in mice.25,27 Preclinical data from the fields of HIV-128,29,30,31,32 and liver-stage malaria vaccine development33,34 also show encouraging results from the combination of adenoviral-vectored and protein-based vaccines. While undertaking the above mouse studies, we also reported that priming with a recombinant adenovirus followed by a booster vaccination with protein-in-adjuvant, greatly reduced the hierarchy of humoral immunogenicity that is typically observed when comparing protein vaccine adjuvants.
Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies
2013, ImmunityCitation Excerpt :The binding of VRC-PG19 and VRC-PG20 to HIV-1 gp120 proteins and competition with other antibodies were accessed with previously described protocols (Wu et al., 2010). Neutralization by VRC-PG19 and VRC-PG20 was measured with single-round-of-infection HIV-1 Env-pseudoviruses containing a luciferase reporter gene to infect TZM-bl target cells that stably expresses high levels of CD4 and the coreceptors CCR5 and CXCR4 (Shu et al., 2007). Neutralization curves were fit by nonlinear regression and the 50% and 80% inhibitory concentrations (IC50 and IC80) were reported as the antibody concentration required to inhibit infection by 50% and 80%, respectively.
The use of adenoviral vectors in gene therapy and vaccine approaches
2022, Genetics and Molecular BiologyTwo-Component Ferritin Nanoparticles for Multimerization of Diverse Trimeric Antigens
2018, ACS Infectious Diseases